Skip to main content
Premium Trial:

Request an Annual Quote

Roche, Fabric Genomics Ink Comarketing Agreement for Whole-Exome Sequencing Solution

NEW YORK – Roche and Fabric Genomics announced on Monday a deal to comarket an integrated whole-exome sequencing solution for hereditary genetics.

Under the terms of the deal, the firms will promote Roche's research-use-only Kapa HyperExome Probes in combination with Fabric's Enterprise bioinformatics and analysis platform. Financial and other terms of the deal were not disclosed.

"Clinical research labs have a need to take a collected sample from library prep quickly, all the way through to analysis, and our agreement with Roche demonstrates our commitment to supporting these critical workflows," Fabric CEO and Cofounder Martin Reese said in a statement. "Using our Fabric Enterprise analysis platform with Roche Kapa HyperExome Probes ensures high coverage of disease-causing genes, which is of the utmost importance in accelerating the identification of rare variants. Combining these technologies into a single workflow will lead to higher quality results and increased reliability of sequencing-based diagnostics in routine care."

Oakland, California-based Fabric offers next-generation sequencing analysis and genomic interpretation.

Fabric said in a statement that the combination of technologies will lower assay development costs for clinical research labs, speed up validation, and "allow laboratories to increase automation and lower operational costs with improved scalability."

Roche launched the HyperExome panel earlier this year as part of its new target enrichment product portfolio.